The concern of generic challenges has consistently loomed above copyright’s famous drug, Sildenafil, sparking questions about the outlook of connected medicinal holdings. While early periods saw significant gains, the patent expiration has created the path for discounted copies, possibly lowering revenue and presenting a real hazard for investors